BE770625A - Procede de preparation d'analgesiques - Google Patents

Procede de preparation d'analgesiques

Info

Publication number
BE770625A
BE770625A BE770625A BE770625A BE770625A BE 770625 A BE770625 A BE 770625A BE 770625 A BE770625 A BE 770625A BE 770625 A BE770625 A BE 770625A BE 770625 A BE770625 A BE 770625A
Authority
BE
Belgium
Prior art keywords
preparation process
analgesic preparation
analgesic
preparation
Prior art date
Application number
BE770625A
Other languages
English (en)
Inventor
I J Pachter
M Gordon
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of BE770625A publication Critical patent/BE770625A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE770625A 1970-08-03 1971-07-28 Procede de preparation d'analgesiques BE770625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6062170A 1970-08-03 1970-08-03

Publications (1)

Publication Number Publication Date
BE770625A true BE770625A (fr) 1972-01-28

Family

ID=22030682

Family Applications (1)

Application Number Title Priority Date Filing Date
BE770625A BE770625A (fr) 1970-08-03 1971-07-28 Procede de preparation d'analgesiques

Country Status (9)

Country Link
US (1) US3773955A (fr)
AU (1) AU463074B2 (fr)
BE (1) BE770625A (fr)
DE (1) DE2138593A1 (fr)
DK (1) DK133035B (fr)
FR (1) FR2101191B1 (fr)
GB (1) GB1353815A (fr)
NL (1) NL7109388A (fr)
ZA (1) ZA714683B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3896226A (en) * 1971-11-26 1975-07-22 Lewinstein Evalina 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3906100A (en) * 1973-05-24 1975-09-16 Miles Lab N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56128715A (en) * 1980-03-06 1981-10-08 Bristol Myers Co Analgesic abuse prevention
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3216327C1 (de) * 1982-05-03 1983-05-19 Siempelkamp Gießerei GmbH & Co, 4150 Krefeld Herstellung von dickwandigen Abschirmtransport- und Lagerbehältern aus sphärolitischem Gußeisen
AU8952282A (en) * 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
DE122004000032I2 (de) 1991-09-06 2006-02-09 Mcneilab Inc Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
US7027859B1 (en) 1994-09-26 2006-04-11 Alza Corporation Electrotransport delivery device having improved safety and reduced abuse potential
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO2001013909A2 (fr) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions et procedes permettant de traiter l'intolerance aux opiaces
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2283842T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
EP1387673B1 (fr) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
ATE345112T1 (de) * 2001-05-11 2006-12-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
CA2496454A1 (fr) * 2002-04-23 2003-11-06 Alza Corporation Systemes analgesiques transdermiques avec risques d'abus reduits
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
WO2004004693A1 (fr) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
SI1551372T1 (en) * 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
JP5501553B2 (ja) 2003-04-21 2014-05-21 ユーロ−セルティーク エス．エイ． 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
BRPI0409945A (pt) 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004112756A1 (fr) 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
AU2004286852A1 (en) 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
US8883204B2 (en) * 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
EP1691892B1 (fr) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Forme posologique co-extrudee inviolable contenant un principe actif et un principe contraire, et procede de fabrication
CA2551127A1 (fr) * 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Traitement de douleur aigue par inhalation en aerosol de medicaments
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DK1729730T3 (da) * 2004-03-30 2009-03-23 Euro Celtique Sa Manipulationssikker doseringsform, der omfatter et adsorberende stof og et kontramiddel
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20070269522A1 (en) * 2004-08-20 2007-11-22 Wold Chad R Transdermal Drug Delivery Device with Translucent Protective Film
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
KR100905511B1 (ko) * 2005-01-28 2009-07-01 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
DK1895994T3 (da) * 2005-05-13 2010-12-20 Alza Corp Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
US20090143761A1 (en) * 2005-06-03 2009-06-04 Transdermal Patents Company, Llc Agent delivery system and uses of same
WO2006133103A2 (fr) * 2005-06-03 2006-12-14 Trans-Dermal Patents Company, Llc Reservoir pour l'administration d'agents
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
WO2007056142A2 (fr) * 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1810670A1 (fr) * 2006-01-19 2007-07-25 Holger Lars Hermann Combinaison de Polamidone et de Naloxone dans le traitement de la toxicomanie
ZA200807571B (en) * 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
US7748244B2 (en) * 2007-09-14 2010-07-06 Schlage Lock Company Deadbolt lock assembly
US20110251229A1 (en) * 2007-10-30 2011-10-13 The Regents Of The University Of Colorado (+)-opioids and methods of use
WO2009059050A2 (fr) * 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Modulateurs de tlr et leurs procédés d'utilisation
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP2014505736A (ja) 2011-02-17 2014-03-06 キューアールエックスファーマ リミテッド 固体投薬形態の乱用を防止するための技術
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
AU2016101552A4 (en) 2015-09-03 2016-10-13 Acino Pharma Ag Reduction of the deallylation of naloxone during the storage of a naloxone-containing retard formulation
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10532385B2 (en) 2016-06-29 2020-01-14 Disposerx, Inc. Disposal of medicaments
ES3064839T3 (en) 2017-11-15 2026-04-29 Univ California Combination of cannabidiol and buprenorphine and its use for the treatment of chronic pain
MX2020007997A (es) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Dispositivo electrico de aerosol de condensacion.
EP4473961A1 (fr) * 2023-06-09 2024-12-11 L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.p.A. Formulation pharmaceutique solide orale comprenant de la méthadone/levométhadone et éventuellement de la naloxone

Also Published As

Publication number Publication date
US3773955A (en) 1973-11-20
AU3185671A (en) 1973-02-01
DK133035B (da) 1976-03-15
FR2101191B1 (fr) 1975-02-07
DE2138593A1 (de) 1972-03-30
ZA714683B (en) 1972-04-26
GB1353815A (en) 1974-05-22
AU463074B2 (en) 1975-07-17
FR2101191A1 (fr) 1972-03-31
NL7109388A (fr) 1972-02-07

Similar Documents

Publication Publication Date Title
BE838223Q (fr) Procede d'hydrodesulfuration
BE763529A (fr) Procede de preparation d'allophanate-polyisocyanates
CH552610A (fr) Procede de preparation d'azapurinones.
BE771169A (fr) Procede de preparation d'isobutylates
BE764883A (fr) Procede de preparation d'hydrogenosilanes
BE760672A (fr) Procede de production d'alcenes
BE786518A (fr) Procede de preparation d'oxa-bicyclo-alcenes
BE770046A (fr) Procede de preparation d'esters polyaryliques
BE774117A (fr) Procede d'etirage
BE766845A (fr) Procede de preparation d'azines
BE777068A (fr) Procede de preparation d'alcoylphenols
BE767990A (fr) Procede de preparation de monochlorobenzaldehydes
BE766195A (fr) Procede de preparation d'acrylonitrile
BE777067A (fr) Procede de preparation d'alcoylphenols
BE761304A (fr) Procede de preparation d'aminophenyl-trial-coxy-silanes
BE764203A (fr) Procede pour la preparation d'indenophtalazines
BE761797A (fr) Procede de preparation de vinyl-trichlorosilane
BE763011A (fr) Procede de preparation de poly-organo-siloxanes
BE768976A (fr) Procede de preparation d'isoprene
BE764210A (fr) Procede de preparation d'alcoyl-silanes
BE792804A (fr) Procede de preparation d'hydroxocobalticorrinoide
BE774593A (fr) Procede de preparation d'enduits
BE777069A (fr) Procede d'obtention d'hydrogenochlorosilanes
BE798180A (fr) Procede de preparation d'anthracenes
BE765104A (fr) Procede de preparation d'ortho. sulfobenzimides